AnGes raising new funds for lead project
This article was originally published in Scrip
Executive Summary
The listed Japanese bioventure AnGes MG is looking to raise up to around JPY5.1 billion ($52.1 million) through the issue of new shares, with the proceeds to be used mainly to support late-stage clinical trials with its lead gene-based biologic therapy.